95 related articles for article (PubMed ID: 2138629)
1. Bone mass reduction after estrogen deprivation by long-acting gonadotropin-releasing hormone agonists and its relation to pretreatment serum concentrations of 1,25-dihydroxyvitamin D3.
Scharla SH; Minne HW; Waibel-Treber S; Schaible A; Lempert UG; Wüster C; Leyendecker G; Ziegler R
J Clin Endocrinol Metab; 1990 Apr; 70(4):1055-61. PubMed ID: 2138629
[TBL] [Abstract][Full Text] [Related]
2. Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH).
Goldray D; Weisman Y; Jaccard N; Merdler C; Chen J; Matzkin H
J Clin Endocrinol Metab; 1993 Feb; 76(2):288-90. PubMed ID: 7679397
[TBL] [Abstract][Full Text] [Related]
3. Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma.
Waibel-Treber S; Minne HW; Scharla SH; Bremen T; Ziegler R; Leyendecker G
Hum Reprod; 1989 May; 4(4):384-8. PubMed ID: 2526152
[TBL] [Abstract][Full Text] [Related]
4. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
Gallagher JC; Fowler SE; Detter JR; Sherman SS
J Clin Endocrinol Metab; 2001 Aug; 86(8):3618-28. PubMed ID: 11502787
[TBL] [Abstract][Full Text] [Related]
5. Biochemical markers as predictors of bone mineral density changes after GnRH agonist treatment.
Borderie D; Cherruau B; Dougados M; Ekindjian OG; Roux C
Calcif Tissue Int; 1998 Jan; 62(1):21-5. PubMed ID: 9405728
[TBL] [Abstract][Full Text] [Related]
6. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.
Mortensen BM; Gordeladze JO; Lyngdal PT; Aarseth HP; Gautvik KM
Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728
[TBL] [Abstract][Full Text] [Related]
7. [Bone mineral content in premenopausal women treated with gonadotropin-releasing hormone analogue].
Masahashi T; Negoro Y; Asai M; Suzuki M; Noguchi M; Nakanishi M; Tomita A
Nihon Sanka Fujinka Gakkai Zasshi; 1992 May; 44(5):577-80. PubMed ID: 1619317
[TBL] [Abstract][Full Text] [Related]
8. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency.
Finkelstein JS; Klibanski A; Schaefer EH; Hornstein MD; Schiff I; Neer RM
N Engl J Med; 1994 Dec; 331(24):1618-23. PubMed ID: 7969342
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral content in girls with precocious puberty treated with gonadotropin-releasing hormone analog.
Verrotti A; Chiarelli F; Montanaro AF; Morgese G
Gynecol Endocrinol; 1995 Dec; 9(4):277-81. PubMed ID: 8629454
[TBL] [Abstract][Full Text] [Related]
10. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
11. Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat.
Mitlak BH; Burdette-Miller P; Schoenfeld D; Neer RM
J Bone Miner Res; 1996 Apr; 11(4):430-9. PubMed ID: 8992873
[TBL] [Abstract][Full Text] [Related]
12. The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer.
Taxel P; Fall PM; Albertsen PC; Dowsett RD; Trahiotis M; Zimmerman J; Ohannessian C; Raisz LG
J Clin Endocrinol Metab; 2002 Nov; 87(11):4907-13. PubMed ID: 12414849
[TBL] [Abstract][Full Text] [Related]
13. [Clinical application of luteinizing hormone releasing hormone agonist and its impact on bone metabolism].
Zhang M; He Y; Cao S
Zhonghua Fu Chan Ke Za Zhi; 1995 Jul; 30(7):398-401. PubMed ID: 7587574
[TBL] [Abstract][Full Text] [Related]
14. Bone densitometry as an adjunct to GnRH agonist therapy.
Cann CE
J Reprod Med; 1998 Mar; 43(3 Suppl):321-30. PubMed ID: 9564668
[TBL] [Abstract][Full Text] [Related]
15. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men.
Leder BZ; Smith MR; Fallon MA; Lee ML; Finkelstein JS
J Clin Endocrinol Metab; 2001 Feb; 86(2):511-6. PubMed ID: 11158001
[TBL] [Abstract][Full Text] [Related]
16. Preservation of bone mass in hypogonadal female monkeys with recombinant human growth hormone administration.
Mann DR; Rudman CG; Akinbami MA; Gould KG
J Clin Endocrinol Metab; 1992 Jun; 74(6):1263-9. PubMed ID: 1592869
[TBL] [Abstract][Full Text] [Related]
17. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
Lee SH; Huang TS; Hsieh SJ
Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D status and sex hormone binding globulin: determinants of bone turnover and bone mineral density in elderly women.
Ooms ME; Lips P; Roos JC; van der Vijgh WJ; Popp-Snijders C; Bezemer PD; Bouter LM
J Bone Miner Res; 1995 Aug; 10(8):1177-84. PubMed ID: 8585420
[TBL] [Abstract][Full Text] [Related]
19. Calcium homeostasis, bone metabolism and safety aspects during long-term treatment with a GnRH agonist.
Eckstein N; Foldes J; Feinstein Y; Vagman I; Eshel A; Steinberg R; Statter M; Limor R; Ayalon D
Maturitas; 1992 Aug; 15(1):25-32. PubMed ID: 1388219
[TBL] [Abstract][Full Text] [Related]
20. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
Heikkinen AM; Parviainen M; Niskanen L; Komulainen M; Tuppurainen MT; Kröger H; Saarikoski S
J Clin Endocrinol Metab; 1997 Aug; 82(8):2476-82. PubMed ID: 9253321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
